Added to YB: 2025-09-01
Pitch date: 2025-08-28
IVVD [bullish]
Invivyd, Inc.
+120.95%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
Market Cap
$547.8M
Pitch Price
$1.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.90
P/E
-5.20
EV/Sales
9.30
Sector
Biotechnology
Category
growth
Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless of Trump Admin Anti-Vaccine Actions
IVVD: COVID mAb developer positioned to replace vaccines as prophylaxis standard. VYD2311 shows 17x higher potency than current Pemgarda, 70+ day half-life enabling IM administration. FDA aligned on single 12-week pivotal trial vs 6mo for vaccines. $80M cash for trial completion, potential CNPV fast-track. Trump admin vaccine ban rumors drove 84% pop. Sub-$200M valuation despite monopoly position in post-vaccine landscape.
Read full article (10 min)